This latest acquisition will allow Atrium to expand its brand portfolio with specialized probiotic niche products
QUEBEC CITY, Jan. 5 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB) is pleased to announce the acquisition of Nutri-Health Supplements, LLC ("NHS"), a fast-growing enterprise located in Cottonwood, Arizona, U.S. This acquisition is in line with Atrium's business development strategy since NHS markets, via multi-channel distribution, specialty niche products endorsed by health professionals.
NHS owns proprietary Multi-Probiotic(R) blends which include 16 powerful probiotic strains that are matrix encapsulated to survive stomach acid and deliver a high concentration of active cell cultures per capsule. During the last few years, NHS has experienced impressive growth and achieved approximately US$27 million in sales for 2008.
Probiotics is currently one of the fastest-growing specialized niches in the food supplement market and have become an important part of nutrition. Human body microbial populations have been altered by the use of substances that are designed to kill germs and disease. By introducing friendly microbes into natural gut flora, the resident micro flora will be strengthened.
The company's brand umbrella includes the Nutri-Health(R) brand which represents about 90% of NHS' total sales. This brand is sold through the direct-to-consumer (DTC) channel largely via a well established mail order program. Furthermore, NHS caters to the health food store and health care practitioner markets with a portfolio of high potential brands - Sedona Labs(R), Meta Foods(R), and Sedona Labs Pro(R).
Atrium has acquired NHS for a first consideration of US$23.9 million fully paid in cash at the closing of the transaction. Two additional earn-out payments have been structured based on NHS' 2009 and 2010 EBITDA growth.
"We are very pleased to acquire Nutri-Health Supplements, an innovative and successful enterprise that is distinguished by a true culture of performance. Nutri-Health has built a loyal and rapidly growing clientele over the years by developing and marketing high quality, health professional-endorsed, specialized products. Buying Nutri-Health marks our first acquisition into the DTC segment with a company aligned with our values and objectives. NHS allows us to acquire complementary expertise in this market segment in which we had a limited business presence until now. This opens the door to promising, synergistic development opportunities within Atrium," said Mr. Pierre Fitzgibbon, President and Chief Executive Officer of Atrium.
Conference Call on the Acquisition
Atrium will hold a conference call and webcast to discuss the NHS acquisition on January 5, 2009 at 4:30 p.m Eastern Standard Time. Participants may access the call using the following numbers: 416-644-3420, 514-807-8791 or 800-733-7571. The live webcast will be available via the Company's website at www.atrium-innov.com found in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days.
Nutri-Health Supplements, LLC is a leading developer, manufacturer and marketer of probiotic and enzymes products. Its premium line of nutraceuticals primarily consists of proprietary Multi-Probiotic(R) blends and enzyme formulations designed to address the specific health needs of consumers, predominantly digestive and immune health. The company primarily markets its products direct-to-consumer through direct mailing but also distributes other brands through specialized retail outlets and healthcare practitioners.
Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 780 employees and operates seven manufacturing facilities. Additional information about Atrium is available on its website at www.atrium-innov.com.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.